Hence, on the basis, we developed a T12/PD-L1 Nb-dual modified liposomal system for SV/Gef brain codelivery to overcome the two formidable barriers in NSCLC treatment--the BMs and drug resistance. This evidence concerns the gene CD274 and non-small cell lung carcinoma.